Navigation Links
Spring Bank Pharmaceuticals Closes $10.5 million Series A Financing to fund Phase I Clinical Trials in HCV-infected Patients
Date:2/28/2013

MILFORD, Mass., Feb. 28, 2013 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced it has closed on a $10.5 million Series A financing.  Proceeds will be used to fund Phase I clinical development of SB 9200, a novel, orally available treatment for Hepatitis C virus (HCV) infection and to further the preclinical pipeline. The Company plans to conduct a Phase I safety and antiviral efficacy study of SB 9200 in healthy, HCV-infected patients beginning in the first quarter of 2013. This financing was led by Brock Securities LLC with participation from Gilford Securities.  

"This financing represents a major milestone for SBP," said Douglas Jensen , CEO and Co-founder of Spring Bank , "as it will enable us to move SB 9200 through an important Phase I clinical study that will provide both safety and early antiviral activity data.  SB 9200 is an entirely new agent for the treatment of chronic HCV infections and is based on our proprietary Small Molecule Nucleic Acid Hybrid (SMNH) technology platform.  We thank our investors for their enthusiastic support and together we look forward to the initiation of our first clinical program and the advancement of our strong pipeline of additional SMNH programs for Hepatitis B virus (HBV), Respiratory Syncytial Virus (RSV), Broad Spectrum Antiviral and COPD."

SB 9200 has a unique mechanism of antiviral action involving the selective activation of the host-immune response in HCV-infected cells.  "Unlike other classes of drugs for HCV infection that act directly on the virus, SB 9200 targets host cytosolic sensor proteins, RIG-I and NOD2," states Dr. Kris Iyer , CSO and Co-founder of Spring Bank .  "This leads to the selective activation of the host immune response in the presence of viral infection. By virtue of this novel mechanism of action, SB 9200 is ideally suited for combination with other classes of HCV antivirals.  In preclinical studies, SB 9200 has shown synergistic antiviral activity when combined with other anti-HCV compounds and has demonstrated an excellent safety profile. Moreover, this novel mechanism of action suggests it could have pan-genotypic activity, as well as potentially a high barrier to resistance. These attributes could potentially lead to the use of SB 9200 as part of an Interferon-free, all-oral regimen for HCV therapy."

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is engaged in the discovery and development of an entirely new class of safer and more effective medicines based on the Company's proprietary SMNH, "Small Molecule Nucleic Hybrid" technology program.  SB 9200, a potential breakthrough drug for the treatment of HCV and HBV, is the Company's most advanced drug under development.  The Company also has programs for the development of antivirals against Respiratory syncytial virus (RSV) infections; the development of a Broad spectrum antiviral; and therapies to treat Chronic obstructive pulmonary disease (COPD).

Contact: Douglas Jensen (508)-473-5993 x105


'/>"/>
SOURCE Spring Bank Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Islet Sciences Announces Strategic Alliance with Spring Point Project
2. Neusoft Medical Launches NeuViz 64 Multi-slice CT Scanner at CMEF Spring 2012
3. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
4. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
5. StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals
6. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
7. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
8. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
9. Jazz Pharmaceuticals Announces Participation At Two Investor Conferences In March
10. Optimer Pharmaceuticals Board of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer
11. Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 ... presentations and one poster presentation at PittCon ... Chicago IL.  Pittcon is the world,s largest ... science and serves a wide array of ... sciences, pharmaceutical discovery and QA, food safety, ...
(Date:2/23/2017)... This report analyzes analyzes the worldwide markets for Wound Debridement Products ... the US, Canada , Japan ... , Latin America , and Rest ... period 2015 through 2022. Also, a six-year historic analysis is ... from primary and secondary research. Company profiles are primarily based ...
(Date:2/23/2017)... NEW YORK , Feb. 22, 2017 Mixed ... The mixed tocopherols market is projected to reach ... from 2016. The market is driven by factors such as ... & beverages and in feed, and regulations for sourcing, processing, ... for mixed tocopherols from emerging markets such as the ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... (PRWEB) February ... for the nation to come together to combine its favorite ... with its favorite fruit – apples! To celebrate National Nutrition ... join the “Apple Madness” bracket tournament – a five-week, five-round ...
(Date:2/23/2017)... ... 23, 2017 , ... Thomas Vas-Don suffered from severe injury due ... was able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ... the principals of massage, anatomy , trigger points and referral pain patterns ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... in recent years. The technology is so cutting edge, in fact, the U.S. ... for stem cell procedures. However, successful patient outcomes in certain clinical stem cell ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients with diabetes ... emergency room, fewer hospital admissions, and better blood pressure and glycemic control, a ... The study can be found here . , The study comes as ...
(Date:2/22/2017)... ... February 22, 2017 , ... Sideline Products participated in the World Horse ... host Tom Seay and his production crew. Tom Seay’s program “Best of America ... world. Saddle Sidekicks will be featured on April 6, 2017. After the broadcast, ...
Breaking Medicine News(10 mins):